CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
ABTL0812 is an innovative oral drug targeting pancreatic cancer, showing efficacy in preclinical studies and early clinical trials. It aims to provide a safe and effective treatment option by inducing cancer cell death without increasing chemotherapy toxicity.
ABTL0812 is a first-in-class fully differentiated oral targeted anticancer compound that produces autophagy-mediated cytotoxicity selectively in cancer cells.
In preclinical studies, ABTL0812 showed efficacy as a single agent and in combination with current standard-of-care treatments in in vitro and animal models of pancreatic cancer, an orphan disease with an urgent unmet clinical need for new efficacious and safe therapies.
Treatment with ABTL0812 induced tumor regression without increasing t…
ABILITY PHARMACEUTICALS SA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
